Top News

Jan 30, 2017
Alexandre Juillerat, PhD, innovation senior scientist at Cellectis, discusses novel construct UCART123, an investigational agent that is on deck to be the first gene-edited T-cell product in the United States.
Jan 26, 2017
By BioPharm International Editors
The companies will split Actelion’s drug discovery and early-stage clinical development assets into a new Swiss biopharmaceutical company.
Jan 24, 2017
Merck will pay a one-time fee of $625 million and additional royalties to BMS and Ono Pharmaceutical to settle the patent infringement case related to Keytruda.
Jan 19, 2017
Researchers were not able to replicate all of the findings in five highly-cited cancer biology papers.
Jan 18, 2017
A new document discusses the exclusivity period for authorized generics, but does not tackle the issue of pay-for-delay agreements.
Jan 17, 2017
FDA released a long-awaited draft guidance to help sponsors seeking to demonstrate interchangeability for biosimilar products.
Jan 11, 2017
Industry experts identify the future focus of the biopharma industry in a new survey.
Jan 05, 2017
By BioPharm International Editors
J&J’s Innovation Global announced the company has entered into 15 new collaborations.
Jan 05, 2017
BioPharm International
The number of novel drugs approved in 2016 by FDA’s CDER department was half the number approved the previous year; many of the complete response letters issued in 2016 were a result of preapproval inspection.
Dec 15, 2016
By BioPharm International Editors
Lonza adds CDMO, capsule, and consumer healthcare and nutrition capabilities with $5.5-billion acquisition of Capsugel.
lorem ipsum